Journal of Oncology / 2018 / Article / Tab 4

Research Article

The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma

Table 4

Comparison of new risk models for progression-free survival using the Heng and MSKCC risk models with 2000 bootstraps.

ModelHarrell’s C indexmean(difference), 95% CI (2.5%, 97.5% of difference)

Model A0.594Model B vs A: 0.017 ( -0.021, 0.057)
Model B0.610

Heng risk model0.614Heng vs Model A: 0.034 ( -0.030, 0.103)
Heng vs Model B: -0.009 ( -0.081, 0.058)
MSKCC risk model0.569mMSKCC vs Model A: -0.025 (-0.106, 0.054)
mMSKCC vs Model B: -0.042 (-0.127, 0.036)

Heng risk model + DRR0.639Heng vs (Heng+DRR): -0.025 ( -0.082, 0.013)

Model C = mMSKCC risk model + AST0.569mMSKCC vs Model C -0.013 (-0.052, 0.015)
Model D = mMSKCC risk model + NLR + DRR0.602mMSKCC vs Model D: -0.046 (-0.117, 0.002)
Model C vs Model D: -0.033 (-0.102, 0.020)

MSKCC, Memorial Sloan Kettering Cancer Center; AST, aspartate transaminase; NLR, neutrophil-to-lymphocyte ratio; CI, confidence interval.
Model A = Nephrectomy, AST.
Model B = Nephrectomy, NLR.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.